Xenon Pharmaceuticals Inc. (XENE) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Burnaby, BC, Canada. वर्तमान CEO हैं Ian C. Mortimer.
XENE के पास है IPO तिथि 2014-11-05, 316 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $4.65B.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's pipeline includes XEN496 and XEN1101, both Kv7 potassium channel openers in clinical development for epilepsy and related conditions, as well as NBI-921352, a sodium channel inhibitor in Phase II trials for developmental and epileptic encephalopathy. Additionally, Xenon is advancing XEN007, a central nervous system calcium channel modulator, and has partnered with Neurocrine Biosciences for epilepsy treatments and Flexion Therapeutics for pain management applications. Founded in 1996, the company is committed to addressing significant unmet medical needs in neurological disorders through its targeted drug development approach.
